Hereditary motor neuropathies

Maike F. Dohrn, Mario Saporta

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


PURPOSE OF REVIEW: Hereditary motor neuropathies (HMN) comprise a broad genotypic and phenotypic spectrum of rare, progressively disabling diseases manifesting with length-dependent muscle weakness and atrophy. To date, more than half of the cases cannot be genetically explained. To provide symptomatic and disease-modifying treatments in the future, a better understanding of disease mechanisms is required. RECENT FINDINGS: By whole exome and genome sequencing, the discovery of several novel genes (SCO2, TDRKH, SPTAN1, CADM3, and SORD) involved in the pathogenesis of HMN has now relevantly changed the pathophysiological knowledge. This recent success in causative understanding has mainly been driven by the development of functional models including cell culture, animal, and patient-derived induced pluripotent stem cell platforms. These models have an important impact on therapeutic advances including broader approaches to prevent or reverse axonal degeneration and individualized gene silencing attempts using sequence-specific RNA degradation mechanisms. SUMMARY: In rare diseases such as HMN, the recent development of genetic sequencing and data interpretation methods has enabled a broader diagnostic approach, whereas treatment strategies are becoming more individualized. Significant milestones have been reached in the discovery of new genes, the establishment of functional disease models, and the preclinical development of mechanistic-based therapies.

Original languageEnglish (US)
Pages (from-to)568-574
Number of pages7
JournalCurrent Opinion in Neurology
Issue number5
StatePublished - Oct 1 2020

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Hereditary motor neuropathies'. Together they form a unique fingerprint.

Cite this